

In 2025, Costs for Medicare Part D Prescriptions Including ORGOVYX[®] May Be Lower and More Predictable¹⁻⁴

How will your patients' out-of-pocket (OOP) drug costs change in 2025?

\$2,000 OOP MAXIMUM

No patient pays more than **\$2,000** for all of their covered Part D prescriptions (**branded and generic**) including ORGOVYX

\$0 OOP COSTS

\$0 costs for covered prescriptions including ORGOVYX **after** your patients reach the yearly OOP maximum of \$2,000

NEW PAYMENT OPTION

Patients can opt in to **split their annual OOP costs (\$2,000) into monthly installments**

Patients can consider managing drug costs with the Medicare Prescription Payment Plan

Free, no-interest program allows patients who opt in to pay monthly installments through the end of the plan year.



Opt in during Medicare open enrollment or anytime during the year



Pay nothing upfront to the pharmacy (including mail order or specialty pharmacies)



Receive a bill from their health plan or Part D drug plan each month (instead of paying the pharmacy)



Patients may opt in to the Medicare Prescription Payment Plan during open enrollment

Do your patients need more information?

- Patients can contact their health plan or Part D plan by using the phone number on the back of their member ID card or visit the plan website
- They can also visit this website: [Medicare.gov](https://www.Medicare.gov)

This resource is for informational purposes only. Contact your patients' health or Part D plans directly for more information about their prescription drug benefits. Sumitomo Pharma America and Pfizer make no guarantees of coverage or reimbursement.

See the next page for examples of how the Medicare changes could lower your patients' OOP costs for ORGOVYX and other covered drugs.

How could your patients' monthly Part D OOP costs change in 2025?^{a,c,d}



WITH THE MEDICARE PRESCRIPTION PAYMENT PLAN...



Meet Malcolm: Malcolm has a Part D plan and is taking ORGOVYX and other covered medications which together cost about \$3,000 a month. If Malcolm opts in to the **Medicare Prescription Payment Plan** during open enrollment, he could spread his \$2,000 yearly OOP maximum (deductible and coinsurance) into 12 monthly installments.^b



Paid to Part D plan

If Malcolm opts in to the payment plan, he pays his Part D plan about **\$167/month (Jan-Dec)** for ALL of his Part D-covered prescriptions.



^a Malcolm is an example patient, for illustrative purposes, and is not based on an actual patient.

^b Monthly payments may vary based on individual plan design and when the patient opts in to the payment plan.

WITHOUT THE MEDICARE PRESCRIPTION PAYMENT PLAN...



If **Malcolm** does not opt in to the **Medicare Prescription Payment Plan** during open enrollment, Malcolm would pay \$2,000 (his deductible and coinsurance) between January and March.



Paid to pharmacy

Malcolm reaches the **\$2,000 OOP maximum in 3 months** and pays **\$0 for ORGOVYX, as well as ALL other Part D-covered prescriptions, for the rest of the year.**



^c Coverage example costs are based on calculations by Sumitomo Pharma America, Inc.

^d The timeframe to reach the \$2,000 OOP maximum and begin paying \$0 for covered prescriptions depends on individual plan benefits and monthly medication costs.



For the lowest possible monthly payments, patients may opt in to the Medicare Prescription Payment Plan during open enrollment. This lets them stretch out payments for as long as 12 months (Jan-Dec 2025)

Medicare's "Extra Help" program assists eligible Part D enrollees with OOP costs

- In 2025, those with Extra Help pay **\$0 premiums, \$0 deductibles**, and reduced copays for prescriptions⁵
 - \$12.15 for brand-name prescriptions** and \$4.90 for generic prescriptions
- Please contact the Part D plan or visit [Medicare.gov](https://www.medicare.gov) or ssa.gov/extrahelp for more information

This resource is for informational purposes only. Contact your patients' health or Part D plans directly for more information about their prescription drug benefits.

Sumitomo Pharma America and Pfizer make no guarantees of coverage or reimbursement.

References: 1. Inflation Reduction Act, Pub. L. No. 117-169, 2022. 2. HHS.gov. Biden-Harris administration releases final part two guidance to help people with Medicare prescription drug coverage manage prescription drug costs. July 16, 2024. Accessed July 31, 2024. <https://www.hhs.gov/about/news/2024/07/16/biden-harris-administration-releases-final-part-two-guidance-help-people-medicare-prescription-drug-coverage-manage-prescription-drug-costs.html> 3. Centers for Medicare and Medicaid Services. Medicare Prescription Payment Plan: final part one guidance. February 29, 2024. Accessed July 17, 2024. <https://www.cms.gov/files/document/medicare-prescription-payment-plan-final-part-one-guidance.pdf> 4. Centers for Medicare and Medicaid Services. Form CMS-10882. Exhibit 1 likely to benefit notice FINAL. July 16, 2024. Accessed July 17, 2024. <https://www.cms.gov/files/zip/medicare-prescription-payment-plan-model-materials.zip> 5. Centers for Medicare and Medicaid Services. Announcement of calendar year (CY) 2025 Medicare Advantage (MA) capitation rates and Part C and Part D payment policies. April 1, 2024. Accessed July 17, 2024. <https://www.cms.gov/files/document/2025-announcement.pdf>



◆ is a trademark of Sumitomo Pharma Co., Ltd., used under license.

SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd. ORGOVYX® and its associated logo are registered trademarks of Sumitomo Pharma Switzerland GmbH.

All other trademarks are the property of their respective owners. © 2024 Sumitomo Pharma Switzerland GmbH and Pfizer Inc. All rights reserved. ORG-US-2266-24 09/24

